The incidence rate and mortality of non-small cell lung cancer are increasing year by year. Some patients are not sensitive to traditional treatment. Today, with the arrival of the era of immunotherapy, the immunotherapy of non-small cell lung cancer is also progressing and developing. This paper mainly reviews the progress of immunotherapy of non-small cell lung cancer in recent years.

Fang Du, Bofan Hu, Peng Xu. Progress in Immunotherapy for Non-small Cell Lung Cancer. Frontiers in Medical Science Research (2022) Vol. 4, Issue 8: 19-23. https://doi.org/10.25236/FMSR.2022.040805.

[1] Jasmine K, Jackson E, L. MA, et al. Immunotherapy for Non-small Cell Lung Cancer (nsclc), as a Stand-alone and in Combination Therapy [J]. Critical Reviews in Oncology/hematology, 2021 (prepublish).

[2] Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl [J]. Med. 378, 1976-1986 (2018).

[3] Zhang Ying, Chen Qian, Shi Yuxia, etc. Application progress of neoadjuvant immunotherapy in non-small cell lung cancer [J]. Anhui Medicine, 2022, 43 (2): 240-243.

[4] Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838-857 (2021).

[5] Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer [J]. N Engl J Med. 2022; 10.1056.

[6] Passiglia F, Bertaglia V, Reale ML, et al. Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon [J]. Cancer Treat Rev. 2021; 101 :102308.

[7] Bai R, Li L, Chen X, Chen N, Song W, Cui J. Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients with Early-Stage Non-small Cell Lung Cancer [J]. Front Oncol. 2020; 10: 575472. Published 2020 Oct 9. 

[8] Cheng Y, Zhang L, Hu J, et al. Pembrolizumab Plus Chemotherapy for Chinese Patients with Metastatic Squamous NSCLC in KEYNOTE-407 [J]. JTO Clin Res Rep. 2021;2(10):100225. Published 2021 Sep 25. 

[9] Zhou C, Wang Z, Sun Y, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial [J]. Lancet Oncol. 2022; 23(2): 220-233. 

[10] Kuznik A, Smare C, Chen CI, et al. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer with Programmed Death-Ligand 1 Expression ≥50 [J]. Value Health. 2022; 25(2): 203-214. 

[11] Ren S, Chen J, Xu X, et al. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial [J]. J Thorac Oncol. 2022; 17(4): 544-557. 

[12] O'Byrne KJ, Lee KH, Kim SW, et al. First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients [J]. ESMO Open. 2022; 7(1): 100394. 

[13] Reck M, Ciulenua T-E, Cobo M, et al. First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA. 2021 ASCO. Abstr 9000.

[14] Three-Drug Regimen Bests Chemo in NSCLC. Cancer Discov [J]. 2021; 11(11): OF2. 

[15] Hegde, P. S., Wallin, J. J. & Mancao, C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin. Cancer Biol. 52, 11 7-124 (2018).

[16] Oyama, T. et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells [J]. Immunol. 160, 1224-1232 (1998).

[17] Reck, M. et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir. Med. 7, 387-401(2019)

[18] Sharma SV, Bell DW, Settleman J, et al. Epidermal grow th factor receptor mutations in lung cancer. Nat Rev Cancer, 2007, 7(3): 169-181. 

[19] West HJ, McCleland M, Cappuzzo F, et al. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. J Immunother Cancer. 2022;10(2): e003027. 

[20] Xue Y, Zheng K, Xue J. Immunotherapy with toripalimab for lung adenocarcinoma in a real-world patient with an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 4: a case report. Ann Palliat Med. 2021; 10(9): 10114-10123.

[21] Xing P, Wang M, Zhao J, et al. Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy. Thorac Cancer, 2021, 12(20): 2825-2828. 

[22] Jiang T, Wang P, Zhang J, et al. Toripalimab plus chemotherapy as second-line treatment in prev iously EGFR-TK I treated patients w it h EGF R-mut a nt-adv a nced NSC L C: a mu lt icenter pha se-II trial. Signal Transduct Target Ther, 2021, 6(1): 355.

[23] HSU P C, JABLONS D M, YANG C T, et al. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1(PDL1) in Non-Small CellLung Cancer (NSCLC) [J]. Int J Mol Sci, 2019, 20(15): 3821-3822.

[24] LIU S Y, WU Y L. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC) [J]. Expert Opin Investig Drugs, 2020, 29(12): 1355-1364.

[25] Jazieh K, Khorrami M, Saad A, et al. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab. J Immunother Cancer. 2022;10(3): e003778. 

[26] Jabbour SK, Lee KH, Frost N, et al. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial [published online ahead of print, 2021 Jun 4]. JAMA Oncol. 2021; 7(9): 1-9. 

[27] Wang N, Zhao L, Zhang D, Jia Y, Kong F. Zhongguo Fei Ai Za Zhi. 2022; 25(3): 214-218. doi: 10.3779/j.issn.1009-3419.2022.102.01.